3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
15
Phase 1/2
15
Phase 1
14
Phase 4
2
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Dermatologic
1
Conditions
Melanoma
3
Neoplasms
2
Skin Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Dexamethasone
8
Oxycodone
6
Epoetin Alfa
5
Propofol
4
Palonosetron
4
Meropenem
4
Zoledronic Acid
3
Vancomycin
3
Sevoflurane
3
Ondansetron
3
Naloxone
3
Everolimus
3
Ciprofloxacin
3
Cholecalciferol
3
Ceftazidime
3
Cefepime
3
Calcium Dobesilate
3
Bevacizumab
3
Aspirin
3
Aprepitant
3
peginterferon alfa-2a
2
edoxaban
2
apixaban
2
apatinib
2
Vitamin B 12
2
Vincristine
2
Tobacco Use Cessation Devices
2
Teicoplanin
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasms
×
Ipilimumab
×
Clear all
NCT06031233
2026-03-30
MINUTE
Isala
Phase 4
Recruiting
776 enrolled
NCT02068196
2023-03-24
Ipi4
Oslo University Hospital
Phase 4
Active not recruiting
150 enrolled